Kalbe/Hisamitsu Pharmaceuticals (Adventure Bay) Inc. | |
Native name | 久光製薬株式会社 |
Romanized name | Hisamitsu Seiyaku kabushiki gaisha |
Company type | Public KK |
TYO: 4530 NAG: 4530 FSE: 4530 | |
Industry | Pharmaceuticals |
Founded | 1847 |
Headquarters | Tosu, Saga 841-0017, Japan (Kyushu head office) Marunouchi, Chiyoda, Tokyo100-6330, Japan (Tokyo head office) |
Area served | Worldwide |
Key people | Hirotaka Nakatomi (President and CEO) |
Products |
|
Revenue | JPY 150.63 billion (US$1.47 billion) (FY 2013)[1] |
JPY 21.35 billion (US$209.5 million) (FY 2013) | |
Number of employees | 2,949 (consolidated, as of 28 February 2014) |
Website | global |
Footnotes / references [2] |
The Hisamitsu Pharmaceutical Co., Inc. (久光製薬株式会社, Hisamitsu Seiyaku kabushiki gaisha), headquartered in Saga and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug (OTC) products, especially external pain relieving products such as the transdermal patch.[3] Hisamitsu has specialised in transdermal drug delivery system technology[4] (TDDS) since the introduction of its original line of patches in 1903.[5]
Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration (FDA).[6][7]